PHAS - PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the upcoming William Blair Biotech Focus Conference 2021 taking place virtually on Thursday, July 15, 2021 at 1:00 pm – 1:45 pm EDT.
The event will be available via live webcast from the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com . The webcast replay will be available for 90 days after the conclusion of the live presentation.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly VIP receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com , and follow us on Twitter @PhaseBio and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005251/en/
PhaseBio Investor Contact:
John Sharp
Chief Financial Officer
(610) 981-6506
john.sharp@phasebio.com
PhaseBio Media Contact:
Will Zasadny
Canale Communications, Inc.
(619) 961-8848
will.zasadny@canalecomm.com